Metabolic Imaging for Brain Cancer

Recruiting in Palo Alto (17 mi)

Overseen byMartin Pike, Ph.D.

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: OHSU Knight Cancer Institute

Disqualifiers: Under 18, others

No Placebo Group

Trial Summary

What is the purpose of this trial?This is an observational study to compare the utility of the novel aMRI approach in human brain to the standard of care imaging approach for diagnosing and assessing glioma. Tumor cells have altered metabolism compared to normal cells.This makes metabolic activity imaging useful for diagnosing and assessing neurological disease. However, current options for metabolic activity imaging are limited. Metabolic activity imaging is primarily conducted using positron emission tomography (PET) with a radioactive tracer called fludeoxyglucose F-18 (¹⁸FDG). A PET scan is a procedure in which a small amount of radioactive glucose (¹⁸FDG) is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where the glucose is taken up. PET imaging is very expensive and is usually much less available than other imaging techniques such as magnetic resonance imaging (MRI). MRI uses radiofrequency waves and a strong magnetic field to provide clear and detailed pictures of internal organs and tissues. While MRI is more available than PET, it isn't as useful in evaluating metabolic activity. Unlike standard MRI, the aMRI approach uses new ways of analyzing MRI images that provides information about tumor cell metabolic activity. Via direct comparison with a standard metabolic imaging approach, ¹⁸FDG PET, this clinical trial will assess the validity of aMRI as a metabolic imaging approach for evaluating neurological disease in patients with glioma.

Eligibility Criteria

This trial is for adults over 18 with gliomas needing MRI and PET scans. It's not for those with sickle cell disease, uncertain pregnancy status, pregnant or breastfeeding women, people unable to consent, overweight beyond equipment limits, metallic/unsafe implants in the body, reduced kidney function (GFR < 45), other risky health conditions as judged by the investigator, poor vein access for IVs, serious illnesses like uncontrolled infections or diabetes type II that could affect study results or compliance.

Inclusion Criteria

I am over 18 and need MRI and PET scans for my glioma.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Imaging

Participants receive ¹⁸FDG IV, then 60 minutes later undergo simultaneous MRI and PET scanning. During this scanning period, patients will receive gadoterate meglumine IV to obtain post-contrast MRI.

1 day

1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after imaging procedures

Up to 1 year

Participant Groups

The trial is testing a new metabolic imaging technique called aMRI against the standard PET scan using fludeoxyglucose F-18 to see if it can effectively evaluate neurological diseases in glioma patients. The goal is to find out if this new method of analyzing MRI images can provide similar information about tumor metabolism as the more expensive and less available PET scans.

1Treatment groups

Experimental Treatment

Group I: Diagnostic (¹⁸FDG PET, MRI)Experimental Treatment4 Interventions

Patients receive ¹⁸FDG IV, then 60 minutes later undergo simultaneous MRI and PET scanning. During this scanning period, patients will receive gadoterate meglumine IV to obtain post-contrast MRI. Total scanning time will take 45-60 minutes.